Beta Bionics (NASDAQ:BBNX) Insider Sells $101,798.97 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 5,327 shares of Beta Bionics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $101,798.97. Following the sale, the insider directly owned 124,027 shares of the company’s stock, valued at $2,370,155.97. This represents a 4.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mark Hopman also recently made the following trade(s):

• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total transaction of $18,882.58.

Beta Bionics Stock Performance

BBNX stock opened at $19.42 on Friday. The company’s 50-day simple moving average is $17.17 and its 200 day simple moving average is $13.65. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71. The company has a market capitalization of $873.71 million, a PE ratio of -11.77 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. On average, analysts forecast that Beta Bionics, Inc. will post -2.1 EPS for the current year.

Wall Street Analysts Forecast Growth

BBNX has been the subject of a number of analyst reports. William Blair began coverage on shares of Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating for the company. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Truist Financial lifted their price objective on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group upped their target price on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Bank of America decreased their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.10.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Beta Bionics in the 1st quarter valued at $95,000. Goldman Sachs Group Inc. acquired a new stake in Beta Bionics in the first quarter valued at about $715,000. Woodline Partners LP bought a new position in Beta Bionics in the first quarter valued at about $1,530,000. Strs Ohio acquired a new position in Beta Bionics during the first quarter worth about $29,000. Finally, Rhumbline Advisers acquired a new position in Beta Bionics during the first quarter worth about $158,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.